Indefinite Delivery Contract 36C77021D0019

The National Acquisition Center of the U.S. Department of Veterans Affairs (VA) has awarded a $32,500,000 Blanket Purchase Agreement (BPA) to Ardelyx, Inc., a pharmaceutical company, for the supply of XPHOZAH (tenapanor), a medication used to treat hyperphosphatemia in patients on dialysis. This single-award BPA, which has an ultimate completion date of April 29, 2026, allows VA medical centers nationwide to efficiently procure the XPHOZAH medication as needed through delivery orders. Ardelyx,...

The National Acquisition Center, a civilian agency of the U.S. Department of Veterans Affairs, awarded a single-award Indefinite Delivery Contract (IDC) to TG Therapeutics Inc., a for-profit pharmaceutical manufacturer, to provide ublituximab-XIIY 150mg/6ml injection, an anti-CD20 antibody, for a 1-year base period and four 1-year option periods through June 16, 2026. The $186,776,520 IDC was awarded on June 17, 2024 with the intent to list the awarded product as the preferred agent on the VA...

This Federal Supply Schedule (FSS) contract was awarded by the Department of Veterans Affairs (VA) to Astellas Pharma US, Inc., a foreign-owned for-profit pharmaceutical manufacturer. The $3.5 billion contract has a period of performance through September 29, 2026 and is for the provision of drugs, pharmaceuticals, and hematology-related products to the VA and potentially other federal agencies. A $296,500 Blanket Purchase Agreement (BPA) was subsequently established against this FSS contract by...

The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite delivery contract to Marlex Pharmaceuticals Inc. to supply probenecid 500mg tablets with a potential value of $5.4 million over a five-year base period and four option years. Place of performance will be in New Castle, Delaware. No set-aside was applied to the original pre-solicitation notice seeking annual supplies of approximately 18,719 bottles of probenecid tablets to support healthcare...

The Department of Veterans Affairs (VA) awarded Daiichi Sankyo, Inc., a for-profit pharmaceutical manufacturer, a Federal Supply Schedule (FSS) contract to supply the drug pexidartinib (marketed as TURALIO) to VA healthcare facilities. The $411.9 million IDV contract, awarded under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB), has an ultimate completion date of October 1, 2025. The VA has placed multiple firm fixed-price delivery orders against this IDV, ranging from $7,593 to...

The Department of Veterans Affairs (VA) awarded Amgen USA Inc., a division of the biotechnology company Amgen Inc., a $3.372 billion Federal Supply Schedule (FSS) contract (36F79721D0086) for the provision of pharmaceuticals, drugs, and hematology-related products. This multiple-award IDV under the GSA Pharmaceuticals and Drugs (FSS-61-IB) schedule allows Amgen to supply these products to various federal agencies. Under this IDV, the VA has issued a $65,478.18 Firm Fixed Price delivery order...

Ardelyx, Inc., a for-profit pharmaceutical company, has been awarded multiple federal contract Indefinite Delivery Vehicles (IDVs) from the U.S. Department of Veterans Affairs (VA) to provide specialized pharmaceutical products, primarily the drug XPHOZAH (tenapanor), to support the healthcare needs of military veterans. The key contracts include a $32,500,000 Blanket Purchase Agreement (BPA) and a $300,000 Federal Supply Schedule (FSS-61-IB) contract, both of which enable Ardelyx to efficiently...

This Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Golden State Medical Supply, Inc., a for-profit manufacturer and distributor of pharmaceuticals and medical products. The contract has a ceiling value of $8,612,710.75 and covers the supply of mycophenolic acid tablets in 180mg and 360mg strengths to the VA, Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS). This single-award IDC has...

This Federal Supply Schedule (FSS) contract, awarded by the U.S. Department of Veterans Affairs (VA), provides for the procurement of pharmaceutical and hematology-related products. The prime contractor, Orexo US Inc., is a for-profit manufacturer based in Morristown, New Jersey. The contract has a ceiling value of $225,000.00 and a period of performance through January 31, 2026. The scope of the contract encompasses the delivery of drugs, pharmaceuticals, and hematology-related products under...

The U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded Scpharmaceuticals Inc., a for-profit pharmaceutical company based in Lexington, MA, a Federal Supply Schedule (FSS) contract valued at $600,875.40. This multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract, designated as FSS 65 IB, covers the provision of drugs, pharmaceuticals, and hematology-related products to VA facilities over a five-year period ending in November 2028. In...